Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2004

01-10-2004 | Article

Improved survival of microencapsulated islets during in vitro culture and enhanced metabolic function following transplantation

Authors: G. S. Korbutt, A. G. Mallett, Z. Ao, M. Flashner, R. V. Rajotte

Published in: Diabetologia | Issue 10/2004

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to determine whether a simple alginate capsule can prolong islet survival and function during long-term tissue culture. We also wanted to observe the ability of these encapsulated islets to restore glucose responsiveness to diabetic recipients, along with the quantity of islets required to do so.

Methods

We compared the recovery and metabolic function of encapsulated canine islets with that of non-encapsulated canine islets following 1, 2 or 3 weeks of tissue culture. These culture preparations were also transplanted into diabetic nude mice and compared for their ability to reverse diabetes. Furthermore, short-term cultured encapsulated and non-encapsulated islets were transplanted in varying numbers to determine the minimum dose required to normalise blood glucose and prolong recipient survival.

Results

Islet recovery following 1, 2 and 3 weeks of tissue culture was significantly higher when islets were encapsulated. When these islets were recovered at 1, 2 and 3 weeks and transplanted into diabetic nude mice, survival at 100 days was 100% for all encapsulated groups, versus 66%, 33% and 33% respectively for the non-encapsulated islets. Additionally, substantially fewer short-term cultured islets were required to normalise blood glucose when the islets were encapsulated. Recipients of encapsulated islets also had significantly longer survival times than recipients of non-encapsulated preparations.

Conclusions/interpretation

This study demonstrates that encapsulation of islets with purified alginate improves islet survival and function in vitro and in vivo.
Literature
1.
Shapiro AM, Lakey JR, Ryan EA et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238CrossRefPubMed
2.
Zhao M, Christie MR, Heaton N, George S, Amiel S, Cai HG (2002) Amelioration of streptozotocin-induced diabetes in mice using human islet cells derived from long-term culture in vitro. Transplantation 73:1454–1460CrossRefPubMed
3.
Schmied BM, Ulrich A, Matsuzaki H et al. (2000) Maintenance of human islets in long-term culture. Differentiation 66:173–180CrossRefPubMed
4.
Tatarkiewicz K, Garcia M, Lopez-Avalos M, Bonner-Weir S, Weir GC (2001) Porcine neonatal pancreatic cell clusters in tissue culture: benefits of serum and immobilization in alginate hydrogel. Transplantation 71:1518–1526CrossRefPubMed
5.
Ao Z, Korbutt GS, Warnock GL, Flashner M, Colby CB, Rajotte RV (1995) Microencapsulation enhances canine islet survival during long-term culture. Transplant Proc 27:3350PubMed
6.
Duvivier-Kali VF, Omer A, Parent RJ, O’Neil JJ, Weir GC (2001) Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes 50:1698–1705PubMed
7.
Ryan EA, Lakey JR, Paty BW et al. (2002) Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 51:2148–2157PubMed
8.
Zimmermann U, Thurmer F, Jork A et al. (2001) A novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Ann NY Acad Sci 944:199–215PubMed
9.
Sun Y, Ma X, Zhou D, Vacek I, Sun AM (1996) Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 98:1417–1422PubMed
10.
Lanza RP, Ecker DM, Kuhtreiber WM, Marsh JP, Ringeling J, Chick WL (1999) Transplantation of islets using microencapsulation: studies in diabetic rodents and dogs. J Mol Med 77:206–210CrossRefPubMed
11.
Van Schilfgaarde R, De Vos P (1999) Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. J Mol Med 77:199–205CrossRefPubMed
12.
King A, Andersson A, Strand BL, Lau J, Skjak-Braek G, Sandler S (2003) The role of capsule composition and biologic responses in the function of transplanted microencapsulated islets of Langerhans. Transplantation 76:275–279CrossRefPubMed
13.
De Vos P, De Haan B, Pater J, Van Schilfgaarde R (1996) Association between capsule diameter, adequacy of encapsulation, and survival of microencapsulated rat islet allografts. Transplantation 62:893–899PubMed
14.
Bunger CM, Gerlach C, Freier T et al. (2003) Biocompatibility and surface structure of chemically modified immunoisolating alginate-PLL capsules. J Biomed Mater Res 67A:1219–1227CrossRefPubMed
15.
Strand BL, Ryan TL, In’t VP et al. (2001) Poly-l-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant 10:263–275PubMed
16.
King A, Lau J, Nordin A, Sandler S, Andersson A (2003) The effect of capsule composition in the reversal of hyperglycemia in diabetic mice transplanted with microencapsulated allogeneic islets. Diabetes Technol Ther 5:653–663CrossRefPubMed
17.
Klock G, Frank H, Houben R et al. (1994) Production of purified alginates suitable for use in immunoisolated transplantation. Appl Microbiol Biotechnol 40:638–643CrossRefPubMed
18.
Wandrey C, Vidal DS (2001) Purification of polymeric biomaterials. Ann NY Acad Sci 944:187–198PubMed
19.
Halle JP, Bourassa S, Leblond FA et al. (1993) Protection of islets of Langerhans from antibodies by microencapsulation with alginate-poly-l-lysine membranes. Transplantation 55:350–354PubMed
20.
Warnock GL, Cattral MS, Rajotte RV (1988) Normoglycemia after implantation of purified islet cells in dogs. Can J Surg 31:421–426PubMed
21.
Yakimets WJ, Lakey JR, Yatscoff RW et al. (1993) Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation 56:1293–1298PubMed
22.
Ricordi C, Gray DW, Hering BJ et al. (1990) Islet isolation assessment in man and large animals. Acta Diabetol Lat 27:185–195PubMed
23.
Ohzato H, Gotoh M, Monden M, Dono K, Kanai T, Mori T (1991) Improvement in islet yield from a cold-preserved pancreas by pancreatic ductal collagenase distention at the time of harvesting. Transplantation 51:566–570PubMed
24.
Korbutt GS, Elliott JF, Ao Z, Smith DK, Warnock GL, Rajotte RV (1996) Large scale isolation, growth, and function of porcine neonatal islet cells. J Clin Invest 97:2119–2129PubMed
25.
Bonner-Weir S, Taneja M, Weir GC et al. (2000) In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 97:7999–8004CrossRefPubMed
26.
Beattie GM, Rubin JS, Mally MI, Otonkoski T, Hayek A (1996) Regulation of proliferation and differentiation of human fetal pancreatic islet cells by extracellular matrix, hepatocyte growth factor, and cell-cell contact. Diabetes 45:1223–1228PubMed
27.
De Vos P, Hillebrands JL, De Haan BJ, Strubbe JH, Van Schilfgaarde R (1997) Efficacy of a prevascularized expanded polytetrafluoroethylene solid support system as a transplantation site for pancreatic islets. Transplantation 63:824–830PubMed
28.
King A, Sandler S, Andersson A, Hellerstrom C, Kulseng B, Skjak-Braek G (1999) Glucose metabolism in vitro of cultured and transplanted mouse pancreatic islets microencapsulated by means of a high-voltage electrostatic field. Diabetes Care 22 [Suppl 2]:B121–B126
29.
Orlowski T, Godlewska E, Moscicka M, Sitarek E (2003) The influence of intraperitoneal transplantation of free and encapsulated Langerhans islets on the second set phenomenon. Artif Organs 27:1062–1067CrossRefPubMed
30.
Del Guerra S, Bracci C, Nilsson K et al. (2001) Entrapment of dispersed pancreatic islet cells in CultiSpher-S macroporous gelatin microcarriers: preparation, in vitro characterization, and microencapsulation. Biotechnol Bioeng 75:741–744CrossRefPubMed
31.
Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, Weir GC (1996) Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 45:1161–1167PubMed
32.
Omer A, Duvivier-Kali VF, Trivedi N, Wilmot K, Bonner-Weir S, Weir GC (2003) Survival and maturation of microencapsulated porcine neonatal pancreatic cell clusters transplanted into immunocompetent diabetic mice. Diabetes 52:69–75PubMed
33.
Martinsen A, Skjak-Baek G, Smidsrod O (1989) Alginate as immobilization material: I. Correlation between chemical and physical properties of alginate. Biotechnol Bioeng 33:79–89
34.
Wu G, Korsgren O, Zhang J, Song Z, Van Rooijen N, Tibell A (2000) Pig islet xenograft rejection is markedly delayed in macrophage-depleted mice: a study in streptozotocin diabetic animals. Xenotransplantation 7:214–220CrossRefPubMed
Metadata
Title
Improved survival of microencapsulated islets during in vitro culture and enhanced metabolic function following transplantation
Authors
G. S. Korbutt
A. G. Mallett
Z. Ao
M. Flashner
R. V. Rajotte
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1531-3

Other articles of this Issue 10/2004

Diabetologia 10/2004 Go to the issue

Short Communication

In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing’s syndrome is associated with increased regeneration of cortisol by 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue

Observation

Sustained glucose-stimulated insulin secretion in mouse islets is not culture-dependent

Article

Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects

Short Communication

Renal disease in rats with Type 2 diabetes is associated with decreased renal nitric oxide production

Article

Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice

Article

High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in Type 1 diabetic pregnancies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits